Evaluation certificate

Request for

Protocol Authorization

Research on Human Beings

Homoclave 04-010, modalities A, C and D.

Research and Clinical Trials

CHANGE CONTROL

Version	Change	Date
1.0	Publication.	May 14, 2024
	EducaPRiS Session. 3rd Session Clinical trials - Frequently Asked Questions.	July 4, 2024
1.1	**Errata:** **In the title:** Homoclave COFEPRIS-04-010, modalities A, C and D. **3. Research documents:** for 3.2. Investigator's Manual references to the research protocol are removed. **4. Sponsor Documents:** 4.1. Letter of express acceptance of the position of sponsor and delegation of responsibilities, 4.4. Document delegating responsibilities from the Sponsor to the importer. **6. Documents from the research center:** 6.2. Authorization letter from the head of the institution where the research protocol will be developed. **In the body of the document (legal basis):** Official Mexican Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals (previously Number(s)). **Inclusion of information in the sections:** **1. Generalities:** information on the modalities of the procedure and the types of protocols that will be accepted in each one. **2. General requirements:** • Clarifications on DIGIPRiS for documents: 2.1. Format of Authorizations, Certificates and Visits and 2.4. Writing of application. • Adding the link for generating payments in: 2. Proof of payment of rights. **3. Research documents:** 3.1. Research protocol: expansion of information in accordance with the ICH guideline: INTEGRATED ADDENDUM TO ICH E6 (R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6 (R2). 3.2. Investigator's manual: expansion of information for medical devices and for the COFEPRIS-04-010 modality d. 3.3. Informed consent. **4. Sponsor Documents:** 4.1. Letter of express acceptance of the position of sponsor and delegation of responsibilities. 4.4. Document delegating responsibilities from the Sponsor to the importer. 4.7. Letter describing import inputs that expresses the approximate quantity of the product to be imported in investigation. **5. Importer and warehouse documents for the product under investigation:** 5.2. Sanitary license for the storage and distribution warehouse for the investigational product: changed from “controlled and biological” to “Only narcotic drugs, psychotropics, biologicals, radiopharmaceuticals and vaccines.” **6. Documents from the research center:** 6.1. Health license or operating notice of the establishment where the research will be carried out: included examples. 6.3. Letter describing the available resources of the center where the research will be carried out: examples are included. **7. Documents from the center where medical emergency care will be carried out:** 7.3. Authorization letter from the owner of the establishment where medical emergencies will be treated. **8. Documents of the main investigator:** 8.2. Professional history of the principal investigator. 8.3. Academic preparation and experience of medical, paramedical and other participating personnel. 8.5. Express letter of no conflict of interest to conduct the research, signed by the principal investigator and his team of work. **9. Documents of the evaluation committees:** 9.2. Favorable opinion issued by each evaluation committee. 9.3. Non-voting letter from the committee members who are part of the research team. 9.4. Express letter of no conflict of interest, and confidentiality of the members of the Committees, regarding the protocol information. **10. Investigational product documents:** 10.1. Information on compliance with Good Manufacturing Practices. 10.2. Research Product Stability. **Updating** the numbering of the documents, to facilitate their identification. **Update** of the foundations to include as references (1) ICH Guide: INTEGRATED ADDENDUM TO ICH E6 (R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6 (R2) and (2) National Guide for the integration and operation of Ethics Committees in Research. Sixth edition, 2018.	July 23, 2024
	Publication.	July 30, 2024

SALUD
SECRETARÍA DE SALUD

COFEPRIS
COMISIÓN FEDERAL PARA LA PROTECCIÓN CONTRA RIESGOS SANITARIOS

Evaluation document for the request for authorization of protocols research on human beings **(COFEPRIS Homoclave 04-010, modalities A, C and D)**

1. Generalities.

The requirements and requirements of this document are named by way of example but not limitation, so it is the responsibility of the applicant for research protocols in human beings to adhere to the mandatory provisions established by the legal framework -
current national health system, in addition to adapting to the scientific and ethical principles that justify the research proposed in accordance with international regulatory instruments, universally accepted depending on the type of study, the phase, the type of product under investigation and other characteristics of the research.

This card is applicable for the evaluation of procedures of the following modalities:

Modality A: Protocol or clinical trial of intervention in human beings that aims to study products or medications under investigation for use in humans, such as: pharmacochemicals, biologicals, biotechnologies, advanced therapies and combinations of these. Clinical research includes the following sequence of studies:

- **Phase I clinical trials:** The administration of an investigational product or medication to humans for the first time, without diagnostic or therapeutic benefit, in single or multiple doses, in volunteers without known significant health problems (healthy people) or in people with the disease or pathology. In most cases, between 20 and 80 volunteers participate in Phase I.

  Phase I studies are closely monitored and information is collected about how a drug interacts with the human body. Researchers adjust dosing schedules based on results from animal research (preclinical studies) to determine how much of the drug the body can tolerate and what its acute side effects are.

  Researchers answer research questions related to: how the investigational product works in the body, side effects associated with increasing the dose, and early information about how effective in order to determine the best way to administer the medication to limit risks and maximize potential risk-benefits (this is important for the design of Phase II studies).

- **Phase II clinical trials:** The administration of an investigational product or medication in small groups of subjects, in single or multiple doses, to determine its initial efficacy and other pharmacological parameters in the body.

  Researchers administer the drug to a group of patients with the disease for which the drug is being developed. These studies, which typically involve a few hundred patients, are not large enough to show whether the drug will be effective, but they do provide researchers with additional safety data.

Researchers use this data to refine research questions, develop research methods, and design new Phase III research protocols.

- **Phase III clinical trials:** The administration of an investigational product or medication to large groups of patients, to define its therapeutic usefulness and identify adverse reactions, interactions and external factors that may alter the pharmacological effect.

  Researchers design phase III studies to demonstrate whether or not a product offers therapeutic benefit to a specific population. These studies involve between 300 and 3000 participants, which are known as pivotal studies.

  Phase III studies provide the majority of safety data. In previous studies, less common side effects may not have been detected. Because these studies are larger and longer in duration, the results are more likely to show rare or long-term side effects.

- **Biocomparability protocols:** Studies, tests, trials and analyzes that are essential to demonstrate that a biocomparable biotechnological medicine has the same quality, safety and efficacy characteristics of a reference biotechnological medicine.

  Clinical biocomparability studies are conducted with the objective of addressing any potential uncertainties and ensuring that there are no clinically significant differences between the proposed biocomparable product and the reference product in terms of safety, purity and potency (i.e. safety and efficacy).).

  The nature and extent of the clinical study(s) will depend on the nature and extent of residual biocomparability uncertainty after performing analytical and in vitro functional characterization.

  One or more clinical studies that directly compare the proposed biocomparable medicine with the innovator or reference biotechnological medicine are generally recommended.

  Examples include clinical pharmacology studies evaluating pharmacokinetic (PK) similarity, pharmacodynamic (PD) similarity, and comparing immunogenicity (i.e., safety); and comparative clinical studies in patients with safety and efficacy evaluations.

  The type and number of studies necessary will depend on the nature of the proposed product.

- **Extension studies (OLE):** Studies conducted after the randomized (blinded) portion of the clinical trial is completed or when the trial has met its objective to demonstrate safety and efficacy, supporting its registration . These studies aim to obtain more data on the safety, tolerability and effectiveness of the treatment in the long term, as well as allowing subjects to continue benefiting from said treatment.

- **NOTES:** If it is
  - an authorized medication (which already has a health registration) and you wish to use it with a therapeutic indication other than the authorized one, you must enter it as MODALITY A.

- Drug-releasing medical devices (that is, devices whose main purpose of use is through pharmacological, immunological or metabolic mechanisms), must be entered as MODALITY A.

Modality C: Study, protocol or clinical trial in human beings, to test new resources and other methods of prevention, diagnosis, treatment and rehabilitation carried out in human beings or their biological products, except pharmacological ones, for example:

- Grafts
- Prosthetics
- Transplants
- Surgical or rehabilitation procedures
- Medical devices (non-drug releasing)
- Medical devices (drug releasers as an auxiliary function, where the purpose of use is NOT determined by pharmacological, immunological or metabolic mechanisms).

Modality D: Risk-free research study, which involves the collection and analysis of information or data from the subjects in which no intervention or intentional modification is made to their physiological, psychological and social variables; and in which documentary research techniques or methods can be used. This includes:

- **Phase IV clinical trials (Post-marketing studies): Studies** that are carried out after the drug or device is granted a Health Registration. They are intended to generate new information about the safety of the drug during its widespread and prolonged use.

  Non-interventional studies, also known as observational studies, contribute substantial evidence of the effectiveness and/or evidence of safety of a medication.

  Type of studies in which participants receive the marketed medications of interest during routine medical practice and are not assigned to an intervention according to a protocol.

This certificate does not include Modality COFEPRIS-04-010-B (Bioequivalence), because it has specific requirements and because the objective in these studies is to evaluate the relationship between two pharmaceutical equivalents or pharmaceutical alternatives when administered under Similar conditions produce similar bioavailabilities (rate and amount of drug absorbed) in generic medications.

The specific card will be published later.

2. General requirements.

2.1. Authorizations, Certificates and Visits Format (FF-COFEPRIS-01)	
ÿ Signed by the accredited legal representative. ÿ Required with the fields corresponding to the sections: o Section 1: Homoclave (04-010) and corresponding modality (A, C or D). o Section 2: Owner information according to tax data. o Section 3: Data on the owner establishment according to the information in the health license, notice of operation or "Information on Establishments that Do not Require to Submit Notice of Operation or License Application" format (only for contract research organizations) . o Section 7: The information presented must be as requested in the free text writing. **NOTE:** In the case of DIGIPRiS, this document is generated automatically when signing the application, once the "OWNER DATA" and "OWNER ESTABLISHMENT DATA" sections have been requested. Said digital version will be available under the name "Application" and can be downloaded after electronically signing the application.	**Compliant:** ÿYes ÿNo
Basis: Federal Law of Administrative Procedure, Article: 15 Mexican Official STANDARD NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Section 6.1 AGREEMENT by which the various procedures and services are made known, as well as the formats applied by the Ministry of Health, through the Federal Commission for the Protection against Sanitary Risks, registered in the Federal Registry of Procedures and Services of the Federal Commission for Regulatory Improvement, published on January 28, 2011.	

2.2. Proof of payment of rights	
ÿ Carried out by the establishment that owns the research. ÿ Addressed to the "Federal Commission for the Protection against Health Risks" agency. ÿ Amount paid for the corresponding request in accordance with the applicable Rate published in the Official Gazette of the Federation. ÿ Voucher payment key. ÿ Date of payment (must be made prior to entering the procedure). ÿ Approval from the banking institution (digital seal or electronic signature). **NOTE:** the link to generate the rights payment format is https://tramiteselectronicos04.cofepris.gob.mx/e5cinco/ (Select the desired option*: [Procedures], Format:* [COFEPRIS-04], Procedure: [010], Subtype: [REQUEST FOR AUTHORIZATION FOR RESEARCH PROTOCOL IN HUMAN BEINGS], Modality: [A, C or D] . Payment key: [400110]).	**Compliant:** ÿYes ÿNo
Basis: Federal Law of Administrative Procedure, Article: 15 Mexican Official STANDARD NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Section 6.1 AGREEMENT by which the various procedures and services are made known, as well as the formats applied by the Ministry of Health, through the Federal Commission for the Protection against Sanitary Risks, registered in the Federal Registry of Procedures and Services of the Federal Commission for Regulatory Improvement, published on January 28, 2011.	

23. Document to prove the address of the owner's establishment	
ÿ Current and updated health license, without suspension in accordance with the Health Licenses Database available at https://www.gob.mx/cofepris/documentos/bases-de-datos-de-licencias-sanitarias-de-insumos -for-health), either ÿ Operation notice (with current and updated entry number, signed by the accredited legal representative), or	**Compliant:** ÿYes ÿNo

ÿ Format for “Information on Establishments That Do Not Require to Submit a Notice of Operation or License Application” and articles of incorporation or power of attorney of the titular establishment, in the case of contract research organizations (CRO).

Basis:
Article 15 of the Federal Law of Administrative Procedure

2.4. Application letter

ÿ Written in free text in which the requested request is briefly, clearly and concisely stated.
ÿ Includes study identification data, risk level and duration (estimated start and end date of the research).

ÿ Signed by the accredited legal representative or authorized person.
ÿ The information contained in the headers and footers must be consistent with the company name and address of the applicant.

NOTE: In the case of DIGIPRiS, this document is requested in editable format (.doc or .docx) to use as a reference for filling out the various fields of the authorization letter. As it forms part of the content of the electronically signed application (through the e.signature), it is preserved without alteration as part of the file and is considered valid even if it does not contain the handwritten signature of the representative or authorized person. It may also contain an electronic signature within the body of the document (“Request Letter”) to replace the handwritten signature, although this does not correspond to an essential requirement for the content of said document.

Compliant:
ÿYes
ÿNo

Basis:
General Health Law, Article: 102, Section: I
Federal Law of Administrative Procedure, Article: 15 and 59.
Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Federal Registry. of Procedures and Services of the Federal Commission for Regulatory Improvement, Third Section, Request for Authorization of Research Protocol on Human Beings, COFEPRIS-04-010-A, COFEPRIS-04-010-C and COFEPRIS-04-010-D .

Regulations of the General Health Law on Health Research, Article: 62, Section: V
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 6.3, 6.3.1, 6.3.2, 6.3.2.4, 6.3.2.9, 8.6

3. Research documents

3.1. Research protocol.

In accordance with the Official Mexican Standard NOM-012-SSA3-2012 and the ICH: INTEGRATED guide ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2):

ÿ **General information:**
- Protocol title*, protocol number*, acronym, document version*, version date* and amendments (if applicable), name and address of the sponsor and monitor (if different from the sponsor).

ÿ **Background and theoretical framework:**
- Name and description of the product under investigation; summary of preclinical findings that have potential clinical significance and are relevant to clinical trials; description and justification of the route of administration, dose, therapeutic regimen and treatment periods; declaration that the clinical trial will be conducted in accordance with the protocol, good clinical practices and local regulatory requirements; problem definition; description of the study population; literature references and relevant trial data; accountability procedure for the management of the investigational product and placebo (if applicable); mechanisms for maintaining randomization and blinding (if applicable), as well as codes for breaking them (for example: criteria for premature unblinding, etc.).

ÿ **Objectives and justification:**
- Detailed description of the objectives and justification for carrying out the protocol and research hypothesis.

Compliant:
ÿYes
ÿNo

ÿ **Study design:**

- Description of the primary and secondary endpoints (outcomes) that will be measured during the study, phase of the study, description of the design (e.g. double-blind, placebo-controlled, parallel, open-label, etc.), schematic diagram of the study, procedures and stages, description of the trial treatments (dose, therapeutic regimen, product packaging and labeling), estimated duration of the research subject's participation and description of the sequence of events (if applicable), description of the reasons for stopping the participation of the subjects in the research, materials and methods.

ÿ **Selection and withdrawal of research subjects:**

- Inclusion criteria; exclusion criteria; criteria for removing the subject from the research (elimination), including procedures that specify when and how they will be removed; indicate what data will be collected and the timing; specify whether there will be replacement of the subjects and how the subjects who withdraw will be followed up (whether due to the decision of the sponsor, the principal investigator or due to withdrawal of informed consent).

ÿ **Therapeutic scheme of the research subjects:**

- Treatment to be administered, including name of the product, dose, route of administration, treatment periods, follow-up periods, medications and treatments allowed and not permitted before and after the trial, procedures to monitor the subject's adherence to the treatment.

ÿ **Efficacy evaluation:**

- Specification of the effectiveness parameters, methods and timing for the evaluation, measurement and analysis of these parameters.

ÿ **Security evaluation:**

- Specification of safety parameters, methods and timing for the evaluation, measurement and analysis of these parameters, procedures for evaluation and reporting of adverse events, type and duration of follow-up after reporting adverse events.

ÿ **Statistical considerations:**

- Description of the statistical methods that will be used, including internal analyzes and their timing, number of subjects planned to be recruited, justification for the sample size including statistical power and clinical rationale, handling procedures for missing data and others, procedures for reporting deviations from the original plan, the selection of subjects to be used in the analysis.

ÿ **Ethical considerations:**

- Description of the ethical considerations in relation to the trial.

ÿ **Capture, processing, analysis and interpretation of the information obtained.**

ÿ **Others:**

- Countries where the research will be carried out, health conditions or problems studied.

ÿ **Study schedule:**

- Document that details the activities to be carried out in an established time to planning, control and management of research.

ÿ **Bibliographic references.**

ÿ **Name and signature of the main researcher and associated researchers.**

***NOTE:** They must coincide with the opinions of the evaluation committees.

Basis:

Regulations of the General Health Law on Health Research; Article: 14; Fraction: I, II, III, IV; Article: 15, 17; Article: 62, Fraction: I; Article: 65, 66, 69, 70, 72, 73, 74; Item: 116, Fraction: I

Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings
Numerals: 5.2, 5.3, 5.5, 5.6, 5.8, 5.9, 5.10, 5.12, 6, 6.2, 6.2.1, 6.2.2, 6.2.3, 6.2.4, 6.2.5, 6.2.6, 6.2.7, 6.2.8, 6.2.9, 6.2.10, 6.2.11, 6.2.12, 6.3, 6.3.2, 6.3.2.1, 6.3.2.2, 6.3.2.3, 10.2

General Health Law, Article: 100, Section: I, II, III; Article: 102, Fraction: II, III, IV

Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Registry. Federal Procedures and Services of the Federal Commission for Regulatory Improvement; Third Section, Request for Authorization of Research Protocol on Human Beings, Homoclaves COFEPRIS-04-010-A, COFEPRIS-04-010-C and COFEPRIS-04-010-D.

See also: INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2)

3.2. Investigator's Manual

ÿ Identification data of the investigational product (investigational product number, generic name of the drug or device, international nonproprietary name, commercial name, if applicable).

ÿ Collection of clinical and non-clinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects. The purpose is to provide investigators and others involved in the trial with information to facilitate their understanding of the rationale for and compliance with key features of the protocol such as: dose, dosing frequency/interval, methods of administration, and monitoring. of security. It also provides information to support the clinical phase design of study subjects during the course of the clinical trial.

ÿ Version of the document and date of the version (coinciding with the approving opinions of the evaluation committees).

ÿ Previously obtained clinical and preclinical information that justifies the use and clinical management of the investigational product.

ÿ **Medications:**
- o Physicochemical and pharmaceutical properties of the product under investigation.
- o Formulation and presentation.
- o Description of the medical device (as applicable).

ÿ **For the COFEPRIS-04-010-D modality:**
- o Prescribing information.

ÿ **Medical devices:**
- o General description of the device and its components.
- o List of accessories (as applicable).
- o Biocompatibility.
- o Security and performance testing.
- o Summary of the manufacturing process.
- o Description of the sterilization process (as applicable).

Note. The information in this document must be presented in a concise, objective and balanced manner that allows the Principal Investigator, as well as others involved in the trial, the suitability of the proposed trial, emphasizing the relevant and updated scientific information of the investigational product such as doses. and interval, method of administration and procedures to monitor participant safety.

Compliant:
ÿYes
ÿNo

Basis:

Regulations of the General Health Law on Health Research; Article: 14, Fraction: II, III; Article: 62, Section: VIII; Item: 66, 67, 68, 69, 70, Item: 73
General Health Law, Article: 100, Section: I, II, III; Article: 102, Fraction: II, III
Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Federal Registry. of Procedures and Services of the Federal Commission for Regulatory Improvement. Third Section, Request for Authorization of Research Protocol on Human Beings, Homoclaves COFEPRIS-04-010-A, COFEPRIS-04-010-C and COFEPRIS-04-010-D
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Section: 5.10

3.3. Informed consent

ÿ Written document, through which the research subject agrees to voluntarily participate in research and have an experimental maneuver applied to them, once they have received sufficient, timely, clear and truthful information about the expected risks and benefits.

ÿ Identification data: Title and protocol number, version, version date, data from the Research Center, name of the principal investigator, data from the medical emergency establishment and data from the Research Ethics Committee (they must coincide with the opinions of the the evaluation committees).

ÿ It must contain, at a minimum, the following information: o Justification and objectives of the research.
- o Explains the blinding of the study (if applicable) and what it consists of.
- o Allocation method.

Compliant:
ÿYes
ÿNo

o Purpose and justification of the procedures to be carried out, mentioning those that correspond to experimental procedures.
o Discomfort and/or expected risks.
o Possible benefits to the participant (physical examination, laboratory and cabinet tests should not be considered as benefits to the participant)
o Alternative procedures that could be advantageous for the subject.
o Contact information (you must specify who to contact, as well as the communication channels and data to request clarification of doubts, or report possible adverse events).

o Include the format or section in the document for the voluntary declaration of informed consent by the participant or their legal representative, by signing express acceptance.

o It must include a section to collect general data (full name, address, relationship with the participant) and signatures of two witnesses of the research subject.

ÿ Guarantee that the research subject:
o You will receive a response for any clarification, concerns and/or questions about the treatment, procedures, risks, benefits and other matters related to the research.

o You retain your right to withdraw your consent at any time to stop participating in the study without prejudice in order to continue with your medical treatment.

o Confidentiality of the information (includes sensitive personal data and those derived from the study).

o The mechanisms to guarantee the availability and continuity of medical treatment, as well as the compensation to which the research subject will be legally entitled in the event of suffering damages directly related to it.

The emergency care center must be included within the Informed Consent, either in the “Identification Data” section or as part of the body of the document.

The information must be presented in a clear, concise manner and in language that is understandable to the participant, which must allow them to understand the risk-benefit of the research in which they are invited to participate.

Basis:

General Health Law; Article: 100, Fraction: IV; Item: 103
Regulations of the General Health Law on Health Research; Article: 14, Fraction: V; Item: 20, 21, 22, 36
Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Federal Registry. of Procedures and Services of the Federal Commission for Regulatory Improvement. Third Section, Section Request for Authorization of Research Protocol in Human Beings, Homoclaves COFEPRIS-04-010-A, COFEPRIS-04-010-C and COFEPRIS-04-010-D
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 4.3, 5.7, 6.3, 6.3.2.10, 8.5, 10.6, 10.7, 11.2, 11.3

See also: National guide for the integration and operation of Research Ethics Committees. Sixth edition, 2018.

4. Sponsor Documents.

4.1. Letter of express acceptance of the position of sponsor and delegation of responsibilities

ÿ Indicates the obligations and rights that the research project or protocol imposes on the sponsor, as well as the responsibilities that the sponsor delegates to those involved in the development of the study.

ÿ The sponsor is the natural or legal person who accepts responsibilities that are expressed in writing, to participate and fully or partially finance a research project or protocol. In addition to accepting the obligations and rights that correspond to the figure of the sponsor.

Compliant:
ÿYes
ÿNo

Basis:

Regulations of the General Health Law on Health Research; Article: 58, Section: III; Item: 120
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 6.3.2.7, 7.2, 11.1

4.2. Follow-up letter on the conduct of the investigation.

ÿ Monitoring and audit plan with the frequency of application
ÿ Person(s) responsible for monitoring
ÿ Objective and scope
ÿ Evaluation tool
ÿ Methodology to carry out scientific, technical and ethical monitoring
ÿ Classification of findings
ÿ Notification mechanisms: to the principal investigator, to the committees and to the authority regulatory.
ÿ Design of the corrective, improvement or preventive action plan, mitigation plan risks, etc.

Compliant:
ÿYes
ÿNo

Basis:
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings; Numeral: 7.2
See also: National guide for the integration and operation of Research Ethics Committees. Fifth edition 2016

4.3. Insurance policy or current document from the financial fund that covers all study participants at the local level.

ÿ Document that guarantees coverage to the subject in case of injury or damage related to research.
ÿ The insurance policy and certificate must indicate the number of subjects that will be covered, title of the study, protocol number and must be in favor of the driver and sponsor.

Compliant:
ÿYes
ÿNo

Basis:
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings; Numerals: 5.14, 7.2

4.4. Document delegating responsibilities from the Sponsor to the importer.

ÿ Sponsor document where the responsibilities and activities of the importer, warehouse, and study owner are delegated (in case this figure is different from the study sponsor).

NOTE: The data are for informational purposes and not for authorization; therefore, those responsible for conducting the study must request, through an independent procedure, the import permit for the product under investigation from the corresponding authority.

Compliant:
ÿYes
ÿNo

Basis:
General Health Law, Articles 194, 295 and 375 Section VIII
Mexican Official STANDARD NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings; Sections 6.4 and 7.2 subsection c
AGREEMENT by which the various procedures and services are made known, as well as the formats applied by the Ministry of Health, through the Federal Commission for the Protection against Sanitary Risks, registered in the Federal Registry of Procedures and Services of the Federal Commission for Regulatory Improvement, published on January 28, 2011.

4.5. Letter of No conflict of interest, which guarantees that it will not lead to the interruption of the treatment of the research participants

ÿ It must be guaranteed that the sponsor will not generate conflicts of interest that could cause the interruption of treatment for the research subject.

Compliant:
ÿYes
ÿNo

Basis:
Regulations of the General Health Law on Health Research, Article: 63, 120
Official Mexican Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Section: 7.4.5

4.6. Letter describing the human and material resources available

ÿ It must be issued by the Sponsor specifying the human and material resources that will be allocated for the research and the way in which they will be provided and distributed to the research centers.
ÿ Describes areas, equipment and auxiliary services of laboratories and cabinets.

Compliant:
ÿYes
ÿNo

Basis:
Regulations of the General Health Law on Health Research, Article: 14, Section: VI
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 6.3.2.4, 7.4.5

4.7. Letter describing import inputs that expresses the approximate quantity to be imported of the product under investigation	
ÿ The information is consistent with the proposed study design. ÿ Document that establishes the quantity and description of imported inputs that will be used during the investigation. **NOTE:** The data are of an informative nature and not of authorization, therefore those responsible for conducting the study must request the import permit through an independent procedure before the corresponding authority.	**Compliant:** ÿYes ÿNo
Basis:	
Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Federal Registry. of Procedures and Services of the Federal Commission for Regulatory Improvement. Third Section General Foreign Trade Rules for 2020, Section: 3.1.4 Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numeral: 6. 4	

5. Documents from the importer and warehouse for the product under investigation.

5.1. Letter of acceptance of responsibility from the importer	
ÿ Express acceptance of responsibilities by the importer. ÿ Signed by the Legal Representative of the importing establishment. ÿ Does not apply if the product under investigation is domestically manufactured.	**Compliant:** ÿYes ÿNo
Basis:	
General Health Law, Articles 194, 295 and 375 Section VIII Mexican Official STANDARD NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Section 6.4 and 7.2	

5.2. Sanitary license for the storage and distribution warehouse for the product under investigation (Only narcotics, psychotropics, biologicals, radiopharmaceuticals and vaccines)	
ÿ Does not apply to products other than narcotics, psychotropics, biologicals, radiopharmaceuticals and vaccines. ÿ Warehouse and distribution license in the National Territory of controlled medications or biological products for human use.	**Compliant:** ÿYes ÿNo
Basis:	
General Health Law, Articles 45, 102, 198, 200 and 257 Mexican Official STANDARD NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Section 8.1	

6. Documents from the research center.

6.1. Health license or operating notice of the establishment where the research will be carried out	
ÿ The operating notice is acceptable if the risk level of the interventions and research procedures are “risk-free.” ÿ In the cases of studies in which the interventions and procedures are considered “with minimal risk” or “risk greater than the minimum” it will be assessed according to the specific case. For example: o Require notice: Weighing the subject, hearing acuity tests, electrocardiogram, thermography, collection of excreta and external secretions, obtaining saliva, deciduous teeth and permanent teeth extracted for therapeutic indication, dental plaque and stones removed by non-invasive prophylactic procedures, cutting of hair and nails without causing disfigurement, blood collection by venipuncture in adults in good health, with a maximum frequency of twice a week and a maximum volume of 450 mL in two months, except during pregnancy, moderate exercise in volunteers healthy, psychological tests on individuals or groups in which the subject's behavior will not be manipulated, research with commonly used medications, wide therapeutic range, authorized for sale, using established indications, doses and routes of administration o Require a license: Obtaining placenta during childbirth, collection of amniotic fluid when membranes rupture, radiological and microwave studies, trials with new devices, studies that include surgical procedures, extraction of blood greater than 2% of the circulating volume in neonates , amniocentesis and other invasive techniques or major procedures. **NOTE:** Based on article 17 of the RLGSMI, investigations are classified into the following categories:	**Compliant:** ÿYes ÿNo

- I.- Risk-free research: These are studies that use retrospective documentary research techniques and methods and those in which no intervention or intentional modification is carried out in the physiological, psychological and social variables of the individuals participating in the study, among them which are considered: questionnaires, interviews, review of clinical records and others, in which they are not identified or sensitive aspects of their behavior are treated;

- II. Minimal risk research: Prospective studies that use risk data through procedures common in physical or psychological examinations for routine diagnosis or treatment, including: subject weighing, hearing acuity testing; electrocardiogram, thermography, collection of excreta and external secretions, collection of placenta during childbirth, collection of amniotic fluid when the membranes rupture, collection of saliva, deciduous teeth and permanent teeth extracted for therapeutic indication, dental plaque and stones removed by non-prophylactic procedures invaders, hair and nail cutting without causing disfigurement, blood collection by venipuncture in adults in good health, with a maximum frequency of twice a week and maximum volume of 450 mL, in two months, except during pregnancy, moderate exercise in healthy volunteers, psychological tests on individuals or groups in which the subject's behavior will not be manipulated, research with commonly used medications, wide therapeutic range, authorized for sale, using established indications, doses and routes of administration and other than investigational medicinal products defined in Article 65 of this Regulation, among others, and

- III.- Research with greater than minimal risk: These are those in which the probabilities of affecting the subject are significant, among which are considered: radiological and microwave studies, trials with medications and modalities defined in article 65. of this Regulation, trials with new devices, studies that include surgical procedures, blood extraction greater than 2% of the circulating volume in neonates, amniocentesis and other invasive techniques or major procedures, those that use random methods of assignment to therapeutic schemes and those that are controlled with placebos, among others.

Basis:

General Health Law; Article: 45, 47; Article: 198, Fraction: IV, V
Official Mexican Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Section: 4.11
General Health Law; Article: 200 Bis, 315, 368, 369, 373
Regulations of the General Health Law on Health Research; Article: 17, 31, 98

6.2. Authorization letter from the head of the institution where the research protocol will be developed

ÿ The head of the institution or establishment grants authorization for it to be carried out.
the research protocol.

Compliant:
ÿYes
ÿNo

Basis:

General Health Law; Article: 102, Fraction: V
Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Federal Registry. of Procedures and Services of the Federal Commission for Regulatory Improvement, Third Section
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 6.3.2.6, 7.2, 8.2, 8.4
Regulations of the General Health Law on Health Research, Article: 14, Section: VI, VIII; Article: 62, Fraction: II, IX

6.3. Letter describing the available resources of the establishment where the research will be carried out

ÿ Describes the available resources of the institution or establishment.
ÿ It should include areas, equipment, auxiliary laboratory services, cabinets, number and type of human resources available, etc.

ÿ When specific procedures are carried out that cannot be carried out in the research center and require other establishments, the following must be indicated: o Procedure(s) to be carried out.

o Company name or name and address of the establishment (Notice of operation or health license, as applicable).

o Name and professional license of the specialist doctor who will perform the procedure.

NOTE: The relevance of the resources and personnel available is variable according to the maneuver to be carried out as part of the investigation. Examples of specific requirements (non-limiting):

- Biotechnology intravenous infusion medication: ACLS certified medical specialist, nurse, red cart, outpatient intravenous medication infusion area, sterile medication preparation hood, dedicated refrigerator for storing medications, etc.

- Lymph node biopsy as part of the investigation: operating room (establishment licensed for surgical procedures), doctor with a specialty in surgical areas (General Surgeon), surgical nurse, anesthesiologist if sedation or anesthesia is required, red cart, exclusive freezer for storage biological samples, recovery area, etc.

- Percutaneous biopsy of deep organs or tissues as part of the investigation: operating room (establishment licensed for surgical acts), doctor with a specialty in surgical areas (General Surgeon) or specialist doctor in the respective area (nephrologist for percutaneous kidney biopsy, gastroenterologist for liver biopsy) or interventional radiologist, ultrasound team, surgical nurse, anesthesiologist in case of

Compliant:
ÿYes
ÿNo

require sedation or anesthesia, red cart, exclusive freezer to store biological samples, recovery area, etc.

• Vaccines: ACLS-certified specialist doctor, nurse, red cart, refrigerator or freezer exclusively for storing medications (according to the storage specifications of the product and what is described in the protocol procedures), etc.

• Intravenous infusion radiopharmaceuticals: establishment licensed to use Radiation Sources for Medical or Diagnostic purposes, doctor specializing in nuclear medicine or related, nurse, red cart, intravenous drug infusion area, hood for the preparation of sterile drugs, dedicated refrigerator to store medicines, etc.

• Intravascular device as an investigational product: operating room (establishment licensed for surgical procedures), specialist doctor (interventional cardiologist if it involves valves or coronary stents, interventional neurologist for neurovascular stents, nephrologist specialized in vascular procedures or vascular surgeon for grafts associated with hemodialysis , vascular surgeon or interventional radiologist for other intravascular devices), surgical nurse, fluoroscopic or ultrasound equipment, anesthesiologist if sedation or anesthesia is required, red cart, recovery area, etc.

Basis:

Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings; Numerals: 6.3.2.4, 7.4.5
Regulations of the General Health Law on Health Research; Article: 14, Fraction: VI, VIII; Article: 62, Fraction: IV, IX
General Health Law, Article: 100, Section: V, VIII
Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Federal Registry. of Procedures and Services of the Federal Commission for Regulatory Improvement. Third Section

7. Documents from the center where medical emergency care will be carried out.

7.1. Health license of the establishment where medical emergency care will be carried out

ÿ Health License for Health Care Establishments where Acts are performed Surgical or Obstetric, valid.
ÿ Does not apply to the protocols of the COFEPRIS-04-010-D modality.

Compliant:
ÿYes
ÿNo

Basis:

General Health Law; Article: 45, 198, 368, 369, 373
Name: Official Mexican Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numeral: 8. 6

7.2. Agreement or contract of the establishment where the medical emergency care of the investigation will be provided

ÿ Current agreement or contract that the institution or establishment has to be able to Provide care for medical emergencies arising from research.
ÿ The details of the emergency center must match the name of the establishment and the address stated in the Health License.

Compliant:
ÿYes
ÿNo

Basis:

Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 6.3.2.9, 8.6
Regulations of the General Health Law on Health Research, Article: 14, Section: X; Article: 62, Fraction: IV, V

7.3. Authorization letter from the owner of the establishment where medical emergencies will be treated

ÿ Contains the acceptance, authorization and description of the available resources of the institution or establishment in which the medical emergencies arising from the research will be attended to.
ÿ The details of the emergency center must match the name of the establishment and the address stated in the Health License.

Compliant:
ÿYes
ÿNo

Basis:

Regulations of the General Health Law on Health Research, Article: 14, Section:
General Health Law, Article: 100, Section: VII

8. Documents of the main investigator.

8.1. Letter of acceptance of responsibility from the principal investigator, of no conflict of interest, of the reporting of adverse events and of confidentiality

ÿ Establishes the acceptance of the principal investigator for the conduct of the clinical protocol, as well as the commitment regarding the reporting of adverse events and the confidentiality of the subjects and the information generated during the research.

Compliant:
ÿYes
ÿNo

Basis:

General Health Law, Article: 100, Section: V
Regulations of the General Health Law on Health Research; Article: 14, Fraction: VI; Article 62, Section: VII; Article: 116, Fraction: V; Article: 117, 118
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings; Numerals: 10.1, 10.4, 10.4.1

8.2. Professional history of the principal investigator

ÿ Updated Curriculum Vitae (CV): Describes the academic training and experience in accordance with the research to be carried out, including academic preparation, representative scientific production (publications in indexed journals) and clinical practice.

ÿ Professional license(s).
ÿ Professional title or equivalent document.
ÿ Good Clinical Practice Certificate (GCP).

The professional license is mandatory, since it is the document in which the government certifies that a person can legally practice their profession, technical specialty or postgraduate degree.

NOTE: Equivalent to the professional title: Specialty diploma, association or collegiate certification, diploma. Intern letters are not accepted.

In the case of professionals who only list their professional ID in their curriculum vitae, this information will be corroborated in the National Registry of Professionals available on the page below:

https://www.cedulaprofesional.sep.gob.mx/cedula/presidencia/indexAvanzada.action.

Compliant:
ÿYes
ÿNo

Basis:

General Health Law, Article: 100
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings; Numerals: 10.1, 10.4.1
Regulations of the General Health Law on Health Research; Article: 14; Fraction: VI
Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Federal Registry. of Procedures and Services of the Federal Commission for Regulatory Improvement. Third Section
Regulations of the General Health Law on Health Research; Article: 62, Fraction: VI; Item: 1113, 114

8.3. Academic preparation and experience of medical, paramedical and other participating personnel

ÿ Updated Curriculum Vitae (CV): describes academic training and experience, includes academic preparation, representative scientific production and clinical practice.
ÿ Professional license, professional title or equivalent document.
ÿ Good Clinical Practice Certificate (GCP).
ÿ Consistent with the activities to be carried out as part of the research team.

The professional license is mandatory, since it is the document in which the government certifies that a person completed their studies and has the knowledge to legally practice their profession, technical specialty or postgraduate degree.

NOTE: Equivalent to the professional title: Specialty diploma, association or collegiate certification, diploma. Intern letters are not accepted.

In the case of professionals who only list their professional ID in their curriculum vitae, this information will be corroborated in the National Registry of Professionals available on the page below: https://www.cedulaprofesional.sep.gob.mx/ cedula/presidencia/indexAvanzada.action.

Compliant:
ÿYes
ÿNo

Basis:

Regulations of the General Health Law on Health Research; Article: 14, Fraction: VI; Article: 62, Fraction: VII, Article: 114, 116, Fraction: V; Article 117, 118
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 10.1, 10.4, 10.4.1
Name: Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Federal Registry of Procedures and Services of the Federal Commission for Regulatory Improvement. Third Section
Other: Section Request for Authorization of Research Protocol in Human Beings, Homoclaves COFEPRIS-04-010-A, COFEPRIS-04-010-C and COFEPRIS-04-010-D
General Health Law; Item: 100, Fraction: V

8.4. Descriptive letter of the delegation of activities and responsibilities from the researcher to the research team	
ÿ Describes the delegation of the activities and responsibilities of each member who participate in the research.	**Compliant:** ÿYes ÿNo
Basis:	
General Health Law, Article: 100, Section: V Regulations of the General Health Law on Health Research; Article: 14, Fraction: VI; Article: 62, Section: VII; Article: 116; Fraction: V; Article: 117, 118 Nor ma Mexican Official NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings; Numerals: 10.1, 10.4, 10.4.1	

8.5. Express letter of no conflict of interest to conduct the research, signed by the principal investigator and his work team	
ÿ Letter that expresses the commitment that no conflicts of interest will be generated that could cause interruption in the treatment of the research subject. ÿ It can be a letter signed by everyone, individual documents, or a document signed by the principal investigator listing and declaring that no member of the research team has a conflict of interest.	**Compliant:** ÿYes ÿNo
Basis:	
Official Mexican Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Section: 7. 4.5 Regulations of the General Health Law on Health Research, Article: 63	

9. Documents of the evaluation committees.

9.1. Records of the Evaluation Committees.	
ÿ Research Ethics Committee (CEI). ÿ Investigation Committee (IC). ÿ Biosafety Committee (CB), if applicable.	**Compliant:** ÿYes ÿNo
Basis:	
General Health Law, Article: 41 bis Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 6.3.2.5, 9, 9.1, 9.1.1, 9.1.2, 9.1.3 , 9.1.4 General Health Law, Article: 98 Regulations of the General Health Law on Health Research, Article: 99, 101, 103, 104, 105, 106, 107, 108	

9.2. Favorable opinion issued by each evaluation committee (applies to CEI, CI and CB)	
ÿ Favorable resolution (approval) based on the ethical aspects, the risk/benefit of the protocol, the guarantee and well-being of the subjects, the technical quality and scientific merit of the research proposed through the approval of the study documents, citing: o Cite the protocol with version and date in Spanish. o Cite the researcher's manual with version and date in Spanish. o Cite the informed consent form(s) with version and date in Spanish. ÿ Opinion signed and issued on letterhead, must include: o The address of the committee, o The date of issuance of the opinion, o Name of the main researcher to whom it is addressed, o The company name and address of the research center, o The title of the study and protocol number, o The status/result of the evaluation of the documents (must be approved), o The name and position of the signatory who endorses the opinion (must be the President or the Secretary Member).	**Compliant:** ÿYes ÿNo
Basis:	
General Health Law, Article: 41 bis; Article: 98; Item: 100, Fraction: I, II, III, IV, V **Regulations of the General Health Law on Health Research, Article: 14, Section: VII, Article: 22; Article: 62, Section: III; Article: 102, 109, 110, 111** **Agreement that modifies the various procedures and services, as well as the formats that apply to the Ministry of Health, through the Federal Commission for the Protection against Health Risks, registered in the Federal Registry. of Procedures and Services of the Federal Commission for Regulatory Improvement, Third Section** **Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 6.3.2.8, 9.2, 9.2.3, 9.2.7, 9.2.8, 9.2 .9, 9.2.11, 9.2.12**	

9.3. Non-voting letter from the committee members who are part of the research team (applies to CEI, CI and CB)	
ÿ All committee members must excuse themselves from participating in the evaluation, approval and issuance of opinions on investigations in which they are participating as part of the investigation team. ÿ Only applies if the committee members are participating in the investigation. ÿ If no member of the research team is part of any of the Committees, send a letter stating that no member of the team is part of any evaluation committee.	**Compliant:** ÿYes ÿNo
Basis:	
Regulations of the General Health Law on Health Research, Article: 108, Section: VII Official Mexican Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Section: 9.2.3	

9.4. Express letter of no conflict of interest, and confidentiality of the members of the Committees, regarding the protocol information (applies to CEI, CI and CB)	
ÿ Committee members must guarantee that no conflict of interest exists or will be generated, as well as guarantee the confidentiality of the information in the research protocol. ÿ Applies to all members who participated in the evaluation and issuance of the corresponding opinion.	**Compliant:** ÿYes ÿNo
Basis:	
Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 9.2.3, 12.1, 12.2, 12.3 Regulations of the General Health Law on Health Research, Article: 108, 112	

9.5. Continuous follow-up letter to the study (applies to CEI, CI and CB)	
ÿ Contains the description of the study monitoring process, which may or may not include the standard operating procedure of the committee.	**Compliant:** ÿYes ÿNo
Basis:	
Regulations of the General Health Law on Health Research, Article: 109 Mexican Official Standard NOM-012-SSA3-2012, Which establishes the criteria for the execution of research projects for health in human beings, Numerals: 7, 7.2, 9.2.3 See also: National guide for the integration and operation of Research Ethics Committees. Sixth edition, 2018.	

10. Investigational product documents.

10.1. Information on compliance with Good Manufacturing Practices	
ÿ Letter under oath, stating that the investigational product and the placebo are manufactured under standards that guarantee that a product is safe for use and that it has the ingredients and potency it claims to have in accordance with the requirements established quality standards, or ÿ Certificate of good practices for the product under investigation, or ÿ Pharmaceutical product certificate. **NOTE: GMP compliance and product stability are not equivalent.** In the case of a letter under oath, it is valid to jointly declare compliance with Good Manufacturing Practices and that the useful life of the investigational product is guaranteed at least until the date of the last administration of the investigational product. and/or placebo.	**Compliant:** ÿYes ÿNo
Basis:	
Official Mexican Standard NOM-164-SSA1-2015, Good drug manufacturing practices, Sections: 16.4.1, 16.4.2, 16.5.1, 16.5.2, 16.5.4, 16.5. 5, 16.10.1 Name: Mexican Official Standard NOM-059-SSA1-2015, Good drug manufacturing practices, Numerals: 10.9, 10.9.1.2, 10.9.1.3, 10.9.2.1, 10.9.2.2, 10.9.2.2.1, 10.9.2.2. 2, 10.9.2.2.3, 10.9.5.1, 10.9.5.2, 10.9.6.1	

10.2. Investigational Product Stability	
ÿ Letter under oath guaranteeing the useful life (stability) of the investigational product from the date of manufacture to the date of the last administration carried out as part of the investigational protocol, or ÿ Protocol and report of results of the accelerated and long-term stability study of the investigational product and placebo, which guarantees its stability from the date of manufacture to the date of the last administration in the research protocol. **NOTE: GMP compliance and product stability are not equivalent.** In the case of a letter under oath, it is valid to jointly declare compliance with Good Manufacturing Practices and that the useful life of the investigational product is guaranteed at least until the date of the last administration of the investigational product. and/or placebo.	**Compliant:** ÿYes ÿNo
Basis:	
Mexican Official Standard NOM-073-SSA1-2015, Stability of drugs and medications, as well as herbal remedies, Numerals: 7.1, 7.2, 10.6, 10.27 Official Mexican Standard NOM-059-SSA1-2015, Good drug manufacturing practices, Section: 10.9.7.1	